Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Qiagen voices satisfaction with ‘solid’ Q1 2014 performance

Qiagen voices satisfaction with ‘solid’ Q1 2014 performance

9th May 2014

Qiagen has announced its financial results for the first quarter of 2014, during which it generated an adjusted net sales total of $317.4 million (188.35 million pounds).

This was up by five percent year on year, with growth achieved across all regions and customer classes. Meanwhile, its adjusted operating income came to $74.8 million, while its adjusted earnings per share were measured at $0.22.

Based on these results, Qiagen has reaffirmed its expectations to deliver higher adjusted net sales and earnings in 2014, with the launch of various new products supporting these ambitious plans.

It also announced a new $100 million share repurchase programme and confirmed the appointment of Dr Werner Brandt named as the new chairman of its supervisory board, succeeding Professor Dr Detlev Riesner.

Peer Schatz, chief executive officer of Qiagen, said the firm is "off to a solid start in the first quarter of 2014 and delivered on targets for higher sales and earnings, moving ahead on strategic initiatives to accelerate innovation and growth while increasing returns to shareholders".

This comes in the same week the company received US regulatory clearance for its new QIAsymphony RGQ MDx system and diagnostic workflow for C. difficile.ADNFCR-8000103-ID-801719189-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.